Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Autoimmune Testing Update | OpenPa…
    Ask Trek AI about this page
    ModifiedMutual of OmahaPolicy AHS-G2022

    Biomarker Testing for Autoimmune Rheumatic Disease

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS-G2022 alerts

    Get alerted when Policy AHS-G2022 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of antinuclear antibody, extractable nuclear antigen, rheumatoid arthritis antibody, and other biomarker testing used to evaluate or monitor systemic autoimmune rheumatic diseases. It applies to individuals whose clinical presentation, laboratory findings, or established diagnoses meet the stated coverage criteria.

    Policy Summary
    PayerMutual of Omaha
    PolicyBiomarker Testing for Autoimmune Rheumatic Disease
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument autoimmune disease symptoms, relevant ANA results and titers, clinical correlation, and the diagnosis or evolving symptoms when repeat testing is requested.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The background, guidelines and recommendations, and evidence-based scientific references were updated.

    Coverage criteria CC11, CC12, and CC13 were edited for clarity and consistency.

    Tissue Specific Markers for Early Diagnosis of Sjögren's Disease were added to CC13.

    CPT code 0522U was added.

    CPT code 81490 was revised.

    1 + 2 lifetimeANA testing limit
    4/yeardsDNA testing limit
    1 + 2 lifetimeRF/anti-CCP testing limit
    5 categoriesExcluded biomarker categories
    0Coverage-criteria modifications in revision summary

    Coverage Criteria

    ANA testing for symptomatic individuals

    Covered when all applicable conditions are met.

    • The individual has signs or symptoms of an autoimmune disease.
    • ANA screening is performed once during the initial workup, or up to two additional times per lifetime when new or more severe signs or symptoms of an autoimmune disease develop.Once initially; up to two additional tests per lifetime for new or more severe symptoms

      Repeat testing is limited by lifetime frequency.

    ENA testing after abnormal ANA

    Covered when all applicable conditions are met.

    ENA panel testing

    • The individual has an abnormal, raised ANA titer and clinical correlation with the appropriate autoimmune disorder.
    • Testing is for specific autoantibodies in an extractable nuclear antigen (ENA) panel.

    RF and anti-CCP testing

    Covered when all applicable conditions are met.

    • The individual has painful and swollen joints suggestive of rheumatoid arthritis.
    • RF and/or anti-CCP testing is performed once during the initial workup, or up to two additional times per lifetime if initial testing did not result in a diagnosis of rheumatoid arthritis and symptoms persist or additional symptoms of rheumatoid arthritis develop.Once initially; up to two additional tests per lifetime in the specified circumstances

      RF and anti-CCP may be tested individually or together.

    dsDNA testing

    Covered when all applicable conditions are met.

    • The individual has an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease.
    • Testing is performed no more than four times per year.Up to four times per year

      Coverage applies to dsDNA testing in the setting of established systemic autoimmune rheumatic disease.

    Condition-specific antibodies with negative or low-positive ANA

    Covered when the stated clinical subset applies.

    Condition-specific antibody testing with negative or low-positive ANA

    • Anti-Jo-1: The individual has a negative or low positive ANA test and is in a unique clinical subset of myositis.
    • Anti-SSA: The individual has a negative or low positive ANA test and has lupus or Sjögren syndrome.

    Not covered testing

    Not covered when any listed condition applies.

    Noncovered testing situations

    • Monitoring disease with ANA testing or ANA titers.
    • ANA and/or ENA testing for individuals without symptoms suggestive of an autoimmune disorder.
    • Specific antibody testing, in situations not otherwise described by the policy, when performed in the absence of a positive ANA test.
    • ANA and/or ENA testing for asymptomatic individuals during a wellness visit or general examination without abnormal findings.
    • Serum biomarkers not otherwise discussed in the policy, alone or in a panel, for diagnosis of rheumatoid arthritis, including a Seronegative Rheumatoid Arthritis Profile.

    ANA monitoring or monitoring disease with ANA titers does not meet coverage criteria.

    ANA and/or ENA testing does not meet coverage criteria for individuals who do not have symptoms suggestive of an autoimmune disorder.

    In situations not otherwise described by the policy, testing for specific antibodies without a positive ANA test does not meet coverage criteria.

    ANA and/or ENA testing does not meet coverage criteria for asymptomatic individuals during a wellness visit or general examination when there are no abnormal findings.

    For diagnosis of rheumatoid arthritis (RA), serum biomarkers not otherwise addressed in the policy—whether tested individually or in a panel—do not meet coverage criteria. This includes the Seronegative Rheumatoid Arthritis Profile.

    Serum biomarker panels designed to manage RA do not meet coverage criteria, including Vectra and PrismRA.

    Cell-bound complement activation products designed to diagnose, prognose, or monitor systemic lupus erythematosus (SLE) do not meet coverage criteria, including AVISE Lupus.

    Serum biomarker panels, with or without proprietary algorithms or index scores, designed to diagnose, prognose, or monitor SLE or connective-tissue diseases do not meet coverage criteria. Examples include AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle DX Disease Activity Index, the Early Sjögren's Syndrome Profile, and Tissue Specific Markers for Early Diagnosis of Sjögren's Disease.

    Testing situations that do not meet the policy's listed coverage criteria do not meet coverage criteria because published scientific literature does not confirm that the tests are required and beneficial for diagnosis and treatment of the individual's illness.

    Covered Clinical Indications

    Signs or symptoms of an autoimmune disease

    Covered when the individual has signs or symptoms of an autoimmune disease.

    ANA screening coverage

    • The individual has signs or symptoms of an autoimmune disease.
    • ANA screening is performed once during the initial workup, or up to two additional times per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.Once initially; up to two additional tests per lifetime for new or more severe symptoms

      Repeat testing is limited by lifetime frequency.

    Abnormal, raised ANA titer with clinical correlation

    Covered when all applicable conditions are met.

    ENA panel testing

    Testing Frequency Limits

    ANA frequency limit
    Initial workupOnce during the initial workup
    Additional testingUp to two additional tests per lifetime
    Requirement for additional testingNew or more severe signs or symptoms of an autoimmune disease must develop
    RF and/or anti-CCP frequency limit
    Initial workupOnce during the initial workup
    Additional testingUp to two additional tests per lifetime
    Requirement for additional testingInitial testing did not result in an RA diagnosis, and symptoms persist or additional RA symptoms develop

    Coding and Reference Thresholds

    Applicable CPT/HCPCS Procedure Codesmixed
    81490Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score; proprietary test: Vectra; Lab/Manufacturer: Labcorp
    81599Unlisted multianalyte assay with algorithmic analysis
    86038Antinuclear antibodies (ANA)
    86039Antinuclear antibodies (ANA); titer
    86200Cyclic citrullinated peptide (CCP), antibody
    86225Deoxyribonucleic acid (DNA) antibody; native or double stranded
    86235Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody
    86430Rheumatoid factor; qualitative
    86431Rheumatoid factor; quantitative
    0039UDeoxyribonucleic acid (DNA) antibody, double stranded, high avidity; proprietary test: Anti-dsDNA, High Salt/Avidity; Lab/Manufacturer: University of Washington, Department of Laboratory Medicine/Bio-Rad
    1–10 of 15
    1/2
    CPT code added in revision historyCPT
    0522UAdded CPT code
    CPT code revised in revision historyCPT
    81490Revised CPT code
    ANA initial workup
    TestANA screening
    FrequencyOnce during the initial workup
    Clinical indicationSigns or symptoms of an autoimmune disease
    Additional ANA testing
    Additional allowanceUp to two additional ANA tests per lifetime
    TriggerNew or more severe signs or symptoms of an autoimmune disease develop
    Testing limit

    Provider Documentation and Action Items

    Documentation Required

    Clinical Indication and Prior Results

    Document autoimmune signs or symptoms and the ANA result before ordering follow-up testing. ANA screening is covered once during the initial workup and up to two additional times per lifetime when new or more severe autoimmune signs or symptoms develop; ENA-specific antibody testing is covered when the ANA titer is abnormally raised and clinically correlates with the appropriate autoimmune disorder.

    • Record the clinical indication, ANA result, and titer.
    • For ENA testing, document the abnormal raised ANA titer and corresponding clinical diagnosis or findings.
    Documentation Required

    Suspected Rheumatoid Arthritis Findings

    For individuals with painful and swollen joints suggestive of rheumatoid arthritis, document the findings supporting RF and/or anti-CCP antibody testing. Testing is covered once during the initial workup and, when initial testing did not establish an RA diagnosis, up to two additional times per lifetime if symptoms persist or additional RA symptoms develop.

    • Document painful and swollen joints and the clinical suspicion of RA.

    Ordering Requirements

    Note

    Order ANA subserologies selectively

    Follow the ACR Choosing Wisely recommendation not to order ANA subserologies without a positive ANA and clinical suspicion of immune-mediated disease.

    Not Covered Services

    The following testing situations are not covered: ANA or ANA-titer monitoring; ANA and/or ENA testing in asymptomatic individuals or individuals without symptoms suggestive of autoimmune disease; specific antibody testing without a positive ANA test outside the listed exceptions; unlisted serum biomarkers or panels for RA diagnosis; serum biomarker panels designed to manage RA, including Vectra and PrismRA; cell-bound complement activation products for SLE, including AVISE Lupus; and serum biomarker panels with or without proprietary algorithms or index scores designed to diagnose, prognose, or monitor SLE or connective-tissue diseases.

    Background

    Systemic autoimmune rheumatic diseases involve dysregulated immunity and inflammation that can damage joints, connective tissue, skin, blood elements, and other organs. ANA testing is commonly used in the initial evaluation for systemic autoimmunity, while disease-specific autoantibodies can support evaluation of conditions such as SLE, Sjögren syndrome, systemic sclerosis, inflammatory myopathies, and RA. Because ANA and other autoantibodies may also occur in healthy individuals, results should be interpreted with clinical findings and other laboratory information rather than used as indiscriminate screening tests.

    Definitions and Clinical Terms

    ANA
    AbbreviationANA
    Full termAntinuclear antibody
    CategoryAn autoantibody used in the evaluation of autoimmune disease
    ENA
    AbbreviationENA
    Full termExtractable nuclear antigens
    Clinical useNuclear antigen targets used to identify autoantibody specificities associated with connective-tissue diseases
    Policy Summary
    PayerMutual of Omaha
    PolicyBiomarker Testing for Autoimmune Rheumatic Disease
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument autoimmune disease symptoms, relevant ANA results and titers, clinical correlation, and the diagnosis or evolving symptoms when repeat testing is requested.
    SourceLink
    On This Page
    Coverage CriteriaCovered Clinical IndicationsTesting Frequency LimitsCoding and Reference ThresholdsProvider Documentation and Action ItemsOrdering RequirementsNot Covered ServicesBackgroundDefinitions and Clinical Terms
    Serum biomarker panel testing designed to manage rheumatoid arthritis, including Vectra and PrismRA.
  1. Cell-bound complement activation products designed to diagnose, prognose, or monitor systemic lupus erythematosus, including AVISE Lupus.
  2. Serum biomarker panel testing, with or without proprietary algorithms or index scores, designed to diagnose, prognose, or monitor systemic lupus erythematosus or connective-tissue diseases, including AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle DX Disease Activity Index, Early Sjögren's Syndrome Profile, and Tissue Specific Markers for Early Diagnosis of Sjögren's Disease.
  3. The individual has an abnormal, raised ANA titer.
  4. There is clinical correlation with the appropriate autoimmune disorder.
  5. Testing is for specific autoantibodies in an ENA panel.
  6. Painful and swollen joints suggestive of rheumatoid arthritis

    Covered when all applicable conditions are met.

    RF and/or anti-CCP testing

    • The individual has painful and swollen joints suggestive of rheumatoid arthritis.
    • Initial or repeat testing

      • Testing is performed once during the initial workup.Once during initial workup
      • Initial testing did not result in a diagnosis of rheumatoid arthritis, and symptoms persist or additional symptoms of rheumatoid arthritis develop.Up to two additional tests per lifetime

        Repeat testing is limited to the specified circumstances.

    Initial positive ANA test and diagnosis of systemic autoimmune rheumatic disease

    Covered when all applicable conditions are met.

    dsDNA testing

    • The individual has an initial positive ANA test.
    • The individual has a diagnosis of systemic autoimmune rheumatic disease.
    • dsDNA testing is performed no more than four times per year.Up to four times per year

    Negative or low positive ANA

    Covered when the stated clinical subset applies.

    • Applicable clinical subset

      • Anti-Jo-1: The individual is in a unique clinical subset of myositis.
      • Anti-SSA: The individual has lupus or Sjögren syndrome.
    dsDNA frequency limit
    Covered frequencyUp to four tests per year
    Prior ANA resultAn initial positive ANA test is required
    Clinical conditionThe individual must have a diagnosis of systemic autoimmune rheumatic disease
    The allowance is cumulative over the individual’s lifetime
    RF and/or anti-CCP initial workup
    TestsRheumatoid factor and/or anti-CCP antibodies
    FrequencyOnce during the initial workup
    Clinical indicationPainful and swollen joints suggestive of rheumatoid arthritis
    Additional RF and/or anti-CCP testing
    Additional allowanceUp to two additional RF and/or anti-CCP tests per lifetime
    Initial resultInitial testing did not result in a diagnosis of rheumatoid arthritis
    Clinical conditionSymptoms persist or additional symptoms of rheumatoid arthritis develop
    dsDNA testing
    Covered frequencyUp to four tests per year
    Prior ANA resultInitial ANA test was positive
    DiagnosisThe individual has a diagnosis of systemic autoimmune rheumatic disease
    MBDA disease-activity categories
    Low activityScore ≤29
    Moderate activityScore 29–44
    High activityScore >44
    1997 ACR SLE classification
    Classification system1997 American College of Rheumatology SLE criteria
    Total criteria11 possible criteria
    Minimum thresholdAt least 4 of 11 criteria
    EULAR/ACR SLE ANA entry criterion
    Entry testAntinuclear antibody testing
    Minimum titerANA titer ≥1:80
    Testing substrateHEp-2 cells or an equivalent positive test
    2012 SLICC SLE classification
    Classification system2012 SLICC Classification Criteria for SLE
    Minimum criteriaAt least 4 criteria
    Required compositionAt least 1 clinical criterion and 1 immunologic criterion
    SLICC SLE classification score
    Minimum scoreAt least 4 criteria
    Clinical requirementAt least 1 clinical criterion
    Immunologic requirementAt least 1 immunologic criterion
  7. For repeat testing, document that initial testing did not result in an RA diagnosis and that symptoms persist or additional symptoms have developed.
  8. Denial Risk

    Asymptomatic or Screening-Only Testing

    ANA and/or ENA testing is not covered for individuals without symptoms suggestive of an autoimmune disorder or for asymptomatic individuals tested during a wellness visit or general examination without abnormal findings.

    • Do not submit ANA or ENA testing as screening in asymptomatic individuals.
    • Document abnormal findings or autoimmune symptoms when present.
    Denial Risk

    ANA Monitoring Not Covered

    ANA testing or ANA-titer testing performed to monitor disease does not meet coverage criteria.

    • Do not order repeat ANA testing solely for disease monitoring.
    Denial Risk

    Unselected Specific Antibody Testing

    Specific antibody testing in the absence of a positive ANA does not meet coverage criteria except for specified situations. For a negative or low-positive ANA, coverage is limited to anti-Jo-1 testing in a unique clinical subset of myositis or anti-SSA testing in the setting of lupus or Sjögren's syndrome.

    • Document a positive ANA before ordering other specific antibodies unless an exception applies.
    • For exceptions, document the applicable clinical subset of myositis, lupus, or Sjögren's syndrome.
    Denial Risk

    Unlisted RA Serum Biomarkers

    For diagnosis of rheumatoid arthritis, serum biomarker testing not otherwise addressed in the policy, whether performed alone or in a panel, does not meet coverage criteria.

    • Do not submit unlisted RA serum biomarkers, including examples such as a Seronegative Rheumatoid Arthritis Profile.
    Denial Risk

    RA Management Panels

    Serum biomarker panels designed to manage rheumatoid arthritis do not meet coverage criteria.

    • Examples include Vectra® and PrismRA.
    Denial Risk

    Cell-Bound Complement Products

    Cell-bound complement activation products designed to diagnose, prognose, or monitor systemic lupus erythematosus do not meet coverage criteria.

    • Example: AVISE Lupus.
    Denial Risk

    SLE and Connective-Tissue-Disease Panels

    Serum biomarker panels designed to diagnose, prognose, or monitor SLE or connective tissue diseases do not meet coverage criteria, whether or not they use proprietary algorithms or index scores.

    • Examples include AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile, and Tissue Specific Markers for Early Diagnosis of Sjögren's Disease.
    SARDs
    AbbreviationSARDs
    Full termSystemic autoimmune rheumatic diseases
    ExamplesSystemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, and rheumatoid arthritis
    RF
    AbbreviationRF
    Full termRheumatoid factor
    Clinical contextAn antibody test used in the evaluation of rheumatoid arthritis
    Anti-CCP
    AbbreviationAnti-CCP
    Full termAnti-cyclic citrullinated peptide
    Clinical contextAn antibody test that may have value in rheumatoid arthritis evaluation
    Anti-dsDNA
    AbbreviationAnti-dsDNA
    Full termAnti-double-stranded DNA
    Clinical contextAn antibody associated with SLE and used following a positive ANA when SLE is suspected
    Jo-1
    AbbreviationJo-1
    Full termHistidyl t-RNA synthetase
    Clinical contextA specific antibody tested in a unique clinical subset of myositis
    CLIA '88
    AbbreviationCLIA '88
    Full termClinical Laboratory Improvement Amendments of 1988
    Regulatory contextCMS regulates laboratory-developed tests as high-complexity tests under CLIA '88
    Antinuclear antibodies (ANA/AAB)
    TargetIntracellular or nuclear structures
    DescriptionAntibodies directed against intracellular or nuclear structures
    Clinical useDetection is used in the evaluation of autoimmune disorders and systemic autoimmune rheumatic diseases
    Indirect immunofluorescence (IIF)
    MethodIndirect immunofluorescence assay
    Cell substrateHEp-2 cells
    Reported findingsAutoantibody binding is reported as staining patterns and titers
    Extractable nuclear antigens (ENA)
    DescriptionNuclear antigen targets extracted using a saline extract of nuclei
    Associated specificitiesSS-A/Ro, SS-B/La, Sm, RNP, Jo-1, and Scl-70
    Clinical useIdentify autoantibody specificities associated with different connective-tissue diseases
    Cell-bound complement activation products (CB-CAPs)
    Full termCell-bound complement activation products
    Measured productsComplement split products measured on erythrocytes and B lymphocytes
    Clinical useIncorporated into certain multianalyte assays for SLE evaluation
    Systemic autoimmune rheumatic diseases (SARDs)
    Full termSystemic autoimmune rheumatic diseases
    Included disordersSLE, systemic sclerosis, Sjögren syndrome, and rheumatoid arthritis
    Clinical contextThe group of rheumatic disorders evaluated in the policy discussion
    MBDA/Vectra DA
    Full termMulti-biomarker disease activity score, also called Vectra DA
    Biomarker countComposite score based on 12 biomarkers associated with RA disease activity
    Interpretation≤29 low, 29–44 moderate, and >44 high disease activity; intended to complement clinical joint assessment
    PrismRA
    Test namePrismRA
    Test typeBiomarker panel
    Intended usePredict inadequate response or non-response to TNF inhibitor therapy in patients with RA
    MAP
    AbbreviationMAP
    Full termMulti-analyte profile
    ComponentsComplement C4d activation products on erythrocytes and B cells combined with serologic disease laboratory tests and autoantibodies
    ANA testing
    ACR positionImmunofluorescence ANA testing using HEp-2 substrate is the gold standard
    Alternative methodsLaboratories using bead-based multiplex or other solid-phase assays should provide comparative sensitivity data on request
    Reporting requirementLaboratories should specify the ANA testing method when reporting results
    2012 SLICC Classification Criteria for SLE
    Criteria count17 criteria divided into clinical and immunologic categories
    Classification thresholdAt least 4 criteria, including at least 1 clinical and 1 immunologic criterion
    TimingCriteria are cumulative and do not need to be concurrently expressed or present
    Rheumatoid arthritis biomarker interpretation
    CRP and ESRIndicate an inflammatory process but have low specificity
    Rheumatoid factorHas low sensitivity and specificity for rheumatoid arthritis
    Seropositive RAAssociated with a worse prognosis than seronegative rheumatoid arthritis